50% OFF

Market Performance and Analysis of Hong Kong Hot Stock Junzi Bio (02367.HK)

#港股热股 #巨子生物 #02367.HK #重组胶原蛋白 #中期业绩
Neutral
HK Stock
December 2, 2025

Unlock More Features

Login to access AI-powered analysis, deep research reports and more advanced features

Market Performance and Analysis of Hong Kong Hot Stock Junzi Bio (02367.HK)

About us: Ginlix AI is the AI Investment Copilot powered by real data, bridging advanced AI with professional financial databases to provide verifiable, truth-based answers. Please use the chat box below to ask any financial question.

Related Stocks

02367.HK
--
02367.HK
--
Comprehensive Analysis

Junzi Bio (02367.HK) is a hot stock in the Hong Kong stock market, mainly based on the following dimensions:

  1. Market Popularity and Trading Activities
    : Included in the East Money App Hong Kong Stock Popularity Ranking [Tushare dc_hot data source]. On December 1, 2025, a large sell order of 149,800 shares was executed at HK$36.58, involving approximately HK$5.48 million. The active trading has attracted attention [1].
  2. Price and Market Performance
    : As of December 2, 2025, the current share price is HK$36.48, down 0.16% [0]. Year-to-date (YTD) gain is 25.66%, and 5-year return is 40.31%, far exceeding the Hang Seng Index’s 3.08% performance over the same period [0].
  3. Fundamental Support
    : 2025 interim results show that profit attributable to shareholders was RMB 1.182 billion, a year-on-year increase of 20.23%, with earnings per share (EPS) of RMB 1.14, representing steady growth [2]. As a pioneer in the recombinant collagen field, it was listed on the Hong Kong Stock Exchange in November 2022 and is known as the “first recombinant collagen stock in Hong Kong” [3].
Key Insights
  1. Industry Position and Market Attention
    : Junzi Bio’s leading position in the recombinant collagen field has made it a focus of market attention, and the growth in interim results has further strengthened investor confidence.
  2. Impact of Large-Scale Transactions
    : The large sell order on December 1, 2025, is an important catalyst for recent stock price fluctuations and rising popularity, possibly reflecting profit-taking or position adjustments by some investors.
  3. Contrast Between Long-Term and Short-Term Performance
    : In the long term, the company’s share price performance is strong, far exceeding the index level, but in the short term, it may fluctuate due to the impact of large-scale transactions.
Risks and Opportunities

Risks
:

  1. Industry Competition Risk
    : It had a product quality dispute with medical beauty giant Bloomage Biotech in June 2025, which affected its share price at that time [3].
  2. Valuation Volatility Risk
    : As a hot stock, increased trading volume may be accompanied by short-term price fluctuations.

Opportunities
:

  1. Industry Growth Potential
    : The recombinant collagen market continues to grow, and the company, as a pioneer, is expected to benefit.
  2. Steady Fundamentals
    : Growth in interim results provides support for the share price.
Key Information Summary
  • Code: 02367.HK
  • Name: Junzi Bio
  • Current Price: HK$36.48 [0]
  • YTD Performance: +25.66% [0]
  • 5-Year Return: 40.31% [0]
  • Interim Net Profit Growth: 20.23% [2]

The above analysis is based on public market data and industry information, providing an objective reference for decision-making.

Previous
No previous article
Next
No next article
Related Reading Recommendations
No recommended articles
Ask based on this news for deep analysis...
Alpha Deep Research
Auto Accept Plan

Insights are generated using AI models and historical data for informational purposes only. They do not constitute investment advice or recommendations. Past performance is not indicative of future results.